Endocrine Journal · 2019 · 13 citations · 13 references
MedicineEndocrinologyOphthalmologyHormone BiochemistryImmunopathologyOcular ImmunologyThyroid DisordersThyroid EndocrinologyThyroid Eye DiseaseAssayBioassay DevelopmentBioassay ValidationGraves Disease EvaluationGraves' Disease EvaluationSerum Thyroid-stimulating Hormone MeasurementThyroid Receptor Antibody TestingThyroid-stimulating Hormone Testing
Graves' ophthalmopathy (GO) is characterized by an autoimmune reaction against thyrotropin (TSH) receptors and is diagnosed by TSH receptor antibody (TRAb). A novel assay for thyroid-stimulating antibody (TSAb) was recently introduced using a frozen Chinese hamster ovary cell line expressing TSH receptors, cyclic adenosine monophosphate (cAMP)-gated calcium channel, and aequorin (aequorin TSAb). The aim of this study was to evaluate the role of aequorin TSAb in GO. We studied 136 Japanese patients with GO (22 euthyroid and 8 hypothyroid GO patients) at our hospital. TRAbs were estimated by first generation TRAb (TRAb 1 st ), second generation TRAb (hTRAb 2 nd ), conventional porcine TSAb, and the new aequorin TSAb assays. Aequorin TSAb, porcine TSAb, TRAb 1 st , and hTRAb 2 nd were positive in 125/136 (92%), 110/136 (81%), 81/130 (62%), and 93/114 (82%) patients, respectively. In patients with hyperthyroid GO, they were positive in 98/106 (98%), 96/106 (91%), 78/101 (77%), and 84/93 (90%) patients, respectively. In patients with euthyroid GO, they were positive in 19/22 (86%), 9/22 (41%), 1/21 (5%), and 6/17 (35%) patients, respectively. Aequorin TSAb levels were significantly related to TRAb 1 st (r = 0.4172, p < 0.0001), hTRAb 2 nd (r = 0.2592, p < 0.0001), and porcine TSAb (r = 0.4665, p < 0.0001). Clinical activity score (CAS) was significantly greater in patients with high titers of aequorin TSAb than in those with low titers. Aequorin TSAb levels were significantly related to the signal intensity ratio of the enlarged eye muscle and proptosis evaluated by MRI before steroid pulse therapy. Aequorin TSAb assay was more sensitive than the conventional assays, especially in euthyroid GO.
13
Teprotumumab for Thyroid-Associated Ophthalmopathy
Terry J. Smith, George J. Kahaly, Daniel G. Ezra et al. · New England Journal of Medicine · 2017 · 721 citations · Full text
Anja Eckstein, Marco Plicht, Hildegard Lax et al. · The Journal of Clinical Endocrinology & Metabolism · 2006 · 480 citations
Management of Graves' Ophthalmopathy: Reality and Perspectives
Luigi Bartalena · Endocrine Reviews · 2000 · 259 citations
Medicine, Ophthalmology, Surgery +12